Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2, Proof of Concept, Randomized, Placebo-Controlled, Parallel Group Study to Evaluate the Effect of Ranolazine and Dronedarone When Given Alone and in Combination on Atrial Fibrillation Burden in Subjects With Paroxysmal Atrial Fibrillation

NCT01522651 is registered in ClinicalTrials.gov with Gilead Sciences as lead sponsor.

NCT NCT01522651
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01522651 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2, Proof of Concept, Randomized, Placebo-Controlled, Parallel Group Study to Evaluate the Effect of Ranolazine and Dronedarone When Given Alone and in Combination on Atrial Fibrillation Burden in Subjects With Paroxysmal Atrial Fibrillation
Lead sponsor
Gilead Sciences
Phase
Phase 2
Overall status
Completed
Start date
January 24, 2012
Completion date
March 10, 2014
Enrollment
134 (actual)
Sites
50

Conditions

As the registry lists them; a condition with its own page is linked.

atrial fibrillation